Literature DB >> 33876299

Post-mortem CMR in a model of sudden death due to myocardial ischemia: validation with connexin-43.

Giovanni Donato Aquaro1, Marco Di Paolo2, Benedetta Guidi3, Khatia Ghabisonia4, Angela Pucci5, Giacomo Aringheri3, Nikoloz Gorgodze4, Musetti Veronica3, Enrica Chiti3, Silvia Burchielli6, Emanuela Turillazzi2, Michele Emdin6,4, Davide Caramella3, Fabio A Recchia6,4.   

Abstract

OBJECTIVES: We sought to evaluate the effectiveness of post-mortem cardiac magnetic resonance (PM-CMR) for the identification of myocardial ischemia as cause of sudden cardiac death (SCD) when the time interval between the onset of ischemia and SCD is ≤ 90 min.
METHODS: PM-CMR was performed in 8 hearts explanted from pigs with spontaneous death caused by occlusion of the left anterior descending coronary artery: 4 with SCD after ≤ 40 min of coronary occlusion and 4 between 40 and 90 min. PM-CMR included conventional T1 and T2-weighted image and T1, T2, and T2* mapping techniques. Imaging data were compared and validated with immunohistochemical evaluation of the altered proportion and redistribution of phosphorylated versus non-phosphorylated connexin 43 (CX43 and npCX43, respectively), an established molecular marker of myocardial ischemia.
RESULTS: At T2-weighted images, the ischemic core was hypointense (core/remote ratio 0.67 ± 0.11) and surrounded by and hyperintense border zone. Compared to remote myocardium, the ischemic core had higher T1 (p = 0.0008), and lower T2 (p = 0.007) and T2* (p = 0.002). Cytoplasmatic npX43 and the npCX43/CX43 ratio were significantly higher in animals deceased > 40 min than in others.
CONCLUSION: PM-CMR can reliably detect early signs of myocardial damage induced by ischemia, based on conventional pulse sequences complemented by a novel ad hoc application of quantitative mapping techniques. KEY POINTS: • Post-mortem MRI may help to understand cause of sudden cardiac death. • Post-mortem MRI allows detection of signs of myocardial ischemia as cause of sudden cardiac death within 90 and 40 min following coronary occlusion as demonstrated in a pig model of myocardial ischemia. • Signs of myocardial ischemia using conventional and mapping MRI technique are associated with the immunohistochemical changes of phosphorylated and dephosphorylated connexin-43 which is an established molecular marker of myocardial ischemia.

Entities:  

Keywords:  Coronary artery disease; Magnetic resonance; Myocardial infarction; Sudden cardiac death

Year:  2021        PMID: 33876299     DOI: 10.1007/s00330-021-07890-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  1 in total

1.  Immunohistochemistry of connexin43 and zonula occludens-1 in the myocardium as markers of early ischemia in autopsy material.

Authors:  Osamu Kawamoto; Tomomi Michiue; Takaki Ishikawa; Hitoshi Maeda
Journal:  Histol Histopathol       Date:  2013-12-24       Impact factor: 2.303

  1 in total
  3 in total

1.  Intracellular Redistribution of Left Ventricular Connexin 43 Contributes to the Remodeling of Electrical Properties of the Heart in Insulin-resistant Elderly Rats.

Authors:  Deniz Billur; Yusuf Olgar; Belma Turan
Journal:  J Histochem Cytochem       Date:  2022-05-24       Impact factor: 4.137

2.  Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc?

Authors:  Arianna Baronti; Francesco Gentile; Alice Chiara Manetti; Andrea Scatena; Silvia Pellegrini; Angela Pucci; Maria Franzini; Vincenzo Castiglione; Aniello Maiese; Alberto Giannoni; Mauro Pistello; Michele Emdin; Giovanni Donato Aquaro; Marco Di Paolo
Journal:  Viruses       Date:  2022-07-27       Impact factor: 5.818

3.  Sudden Cardiac Death and Ex-Situ Post-Mortem Cardiac Magnetic Resonance Imaging: A Morphological Study Based on Diagnostic Correlation Methodology.

Authors:  Giuseppe Bertozzi; Francesco Pio Cafarelli; Michela Ferrara; Nicola Di Fazio; Giuseppe Guglielmi; Luigi Cipolloni; Federico Manetti; Raffaele La Russa; Vittorio Fineschi
Journal:  Diagnostics (Basel)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.